Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
536 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,297 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (216)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07536815 | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC) | available | — | — | CytoDyn, Inc.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Apr 27, 2026source: clinicaltrials